In response to internal concerns raised by employees at the Food and Drug Administration (FDA), top drug regulator George Tidmarsh recently reassured staff of efforts to stabilize resources and bring operations back to normalcy. These concerns primarily revolved around staffing issues, impromptu expert meetings, and the impact of recent organizational changes on the workforce.
During a town hall meeting with the Center for Drug Evaluation and Research (CDER) staff, questions were posed regarding the restoration of funding for research fellows, the resumption of conference attendance, and the shift towards ad-hoc panels rather than traditional advisory committee meetings with clear conflict of interest guidelines for experts.
With the recent appointment of George Tidmarsh as the director of CDER and the Center for Biologics Evaluation and Research following the departure of Vinay Prasad, concerns were expressed regarding the significant workforce reductions the FDA faced in April, leading to a depleted workforce and subsequent strain on regulatory functions.
Employees highlighted specific challenges arising from staff reductions, such as the loss of key personnel affecting crucial programs like drug-induced liver injury tracking and the overall strain on remaining employees who have had to work excessively long hours to compensate for the loss of colleagues.
Tidmarsh assured employees of no further reductions in force and committed to actively filling vacant positions, while emphasizing a collaborative approach with staff to address concerns and improve the agency’s operations. Efforts are underway to retain research fellows, hire more staff, and streamline processes to enhance efficiency.
Questions were raised about the unconventional expert meetings being held outside the traditional advisory committee framework, with concerns about transparency, conflict of interest disclosure, and the dominance of experts skeptical of mainstream medicine. While Tidmarsh acknowledged the importance of advisory committees, he also expressed a need to reassess their value in certain contexts to streamline decision-making processes.
Tidmarsh emphasized his commitment to following scientific principles over political influence, although acknowledging the possibility of being overruled by higher political authorities. The FDA’s leadership, including Tidmarsh and Commissioner Marty Makary, welcomed staff input and sought innovative ideas to enhance their new priority review program.
Key Takeaways:
– FDA under new leadership aims to stabilize resources and address staffing concerns to enhance regulatory functions.
– Efforts are underway to streamline processes, retain research fellows, and fill vacant positions to improve operational efficiency.
– Concerns raised about impromptu expert meetings outside the traditional advisory committee framework, prompting a reassessment of decision-making processes.
– Commitment to scientific integrity remains a top priority despite potential political influences on regulatory decisions.
Tags: biotech
Read more on statnews.com